| HOME >> MEDICINE >> TECHNOLOGY |
1,8751,875Total revenues
152,714174,136Costs and expenses: Cost of goods sold
12,54420,502 Selling, general and administrative
64,62573,313 Research and development
41,91545,261 Collaborative profit sharing
59,85167,900 Restructuring
2,858–Total costs and expenses
181,793206,976Operating loss
(29,079)(32,840)Interest and other income, net
(8,245)(5,363)Net loss
$ (37,324)$ (38,203)Net loss per share - basic and diluted
$
(0.26)$
(0.27)Shares used in computing net loss per share - basic and diluted
144,787142,702A reconciliation of reported GAAP operating loss to non-GAAP operating loss excluding non-cash and other items is provided in the table that follows (in thousands, unaudited):Quarter EndedMarch 31,20112010GAAP operating loss
$(29,079)$(32,840)Stock-based compensation
7,9179,703Other non-cash compensation
4,2387,088Depreciation and amortization
12,71214,153Amortization of deferred revenue
(1,875)(1,875)Restructuring
2,858–Non-GAAP operating loss
$ (3,229)$(3,771)AMYLIN PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)March 31,December 31,20112010AssetsCash, cash equivalents and short-term investments
$
460,158
$
442,663Restricted cash
15,000
15,000Accounts receivable, net
51,926
54,645Inventories, net
109,486
118,629Other current assets
31,923
45,458Property and equipment, net
811,295
811,745Other assets
42,103
43,289Total assets
$
,521,891
$
,531,429Liabilities and stockholders' equity Current liabilities
$
390,282
$
401,595Other liabilities, net of current portion
317,387
317,654Long-term debt
475,298
468,697Stockh
'/>"/>
| SOURCE Amylin Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |